ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Diagnostic performance of commercially available COVID-19 serology tests in Brazil.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tests for Border Screening During the Very Early Phase of Coronavirus Disease 2019 Pandemic: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Performance of Three Commercial Rapid Diagnostic Tests for Detection of IgM and IgG Antibodies Against SARS-CoV-2.Immunity, inflammation and disease · 2026Article
- Occlusion body-incorporated SARS-CoV-2 S-RBD via cypovirus polyhedrin-derived peptide: a novel insect cell-expressed antigen for high-accuracy COVID-19 diagnosis, and humoral immune response and hybrid immunity evaluation.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Endogenous Biomarkers Analysis and False-Negative Results for SARSCov2 Using two Commercial RT-PCR Diagnostic Kits.Iranian journal of pathology · 2026Article
- Serological Assays Reveal No Evidence of Natural SARS-CoV-2 Infection in US Cattle.Microorganisms · 2025Article
- Review
- From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.Vaccines · 2024Review
- The seroprevalence of SARS-CoV-2 infection in Malaysia: 7 August to 11 October 2020.Influenza and other respiratory viruses · 2023Article
- Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Rapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- Prevalence of Malaria and Covid-19 in Febrile Patients in Lomé, Togo in 2020.Acta parasitologica · 2022Article
- Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail.Scientific reports · 2022Article
- Equitable distribution of SARS-CoV-2 tests.Bulletin of the World Health Organization · 2022Article
- Multiplexed flow cytometric approach for detection of anti-SARS-CoV-2 IgG, IgM and IgA using beads covalently coupled to the nucleocapsid protein.Letters in applied microbiology · 2022Article
- Article
- Diagnostic Performance of Seven Commercial COVID-19 Serology Tests Available in South America.Frontiers in cellular and infection microbiology · 2022Article
- Clinical Performance of Three Commercial SARS-CoV-2 Rapid Antigen Tests for Community-Dwelling Individuals in a Tropical Setting.Frontiers in cellular and infection microbiology · 2022Article
- Strengthening government's response to COVID-19 in Indonesia: A modified Delphi study of medical and health academics.PloS one · 2022Article
- Perspectives on electrochemical biosensing of COVID-19.Current opinion in electrochemistry · 2021Review
- A systematic review and meta-analysis of the sensitivity of antibody tests for the laboratory confirmation of COVID-19.Future virology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely and accurate laboratory testing is essential for managing the global COVID-19 pandemic. Reverse transcription polymerase chain reaction remains the gold-standard for SARS-CoV-2 diagnosis, but several practical issues limit the test's use. Immunoassays have been indicated as an alternative for individual and mass testing.
objectivesTo access the performance of 12 serological tests for COVID-19 diagnosis.
methodsWe conducted a blind evaluation of six lateral-flow immunoassays (LFIAs) and six enzyme-linked immunosorbent assays (ELISAs) commercially available in Brazil for detecting anti-SARS-CoV-2 antibodies.
resultsConsidering patients with seven or more days of symptoms, the sensitivity ranged from 59.5% to 83.1% for LFIAs and from 50.7% to 92.6% for ELISAs. For both methods, the sensitivity increased with clinical severity and days of symptoms. The agreement among LFIAs performed with digital blood and serum was moderate. Specificity was, in general, higher for LFIAs than for ELISAs. Infectious diseases prevalent in the tropics, such as HIV, leishmaniasis, arboviruses, and malaria, represent conditions with the potential to cause false-positive results with these tests, which significantly compromises their specificity.
conclusionThe performance of immunoassays was only moderate, affected by the duration and clinical severity of the disease. Absence of discriminatory power between IgM/IgA and IgG has also been demonstrated, which prevents the use of acute-phase antibodies for decisions on social isolation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.